Browsing Tag
ADC Therapy
4 posts
Half of platinum-resistant ovarian cancer patients respond to Raludotatug deruxtecan in REJOICE-Ovarian01 trial
Find out how Raludotatug deruxtecan achieved a 50 % response rate in platinum-resistant ovarian cancer and what it means for future ADC therapies.
InnoCare Pharma receives Chinese IND clearance for novel B7-H3 targeted ADC ICP-B794 to treat solid tumors
InnoCare Pharma gains Chinese IND approval for ICP-B794, a novel B7-H3 targeted ADC for solid tumors including lung and prostate cancer.
Taiho Pharmaceutical to expand ADC portfolio with Araris Biotech acquisition
Taiho Pharmaceutical is acquiring Araris Biotech for $1.14 billion, strengthening its ADC oncology pipeline. Discover how this deal is shaping the future of cancer treatment.
Akeso completes patient enrollment for Phase III Cadonilimab trial in high-risk HCC
Akeso, Inc. has announced the completion of patient enrollment for its Phase III cadonilimab trial (COMPASSION-22/AK104-306), marking a…